Chapter/Section Purchase

1 Study Coverage
1.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Product Introduction
1.2 Market by Type
1.2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Recombinant Monoclonal Antibodies
1.2.3 In-House Bispecific Antibodies
1.3 Market by Application
1.3.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Immunotherapy of Cancer
1.3.3 Clinical Experiment
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Estimates and Forecasts 2017-2028
2.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Estimates and Forecasts 2017-2028
2.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region
2.4.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region (2017-2022)
2.4.2 Global Sales T-Cell & NK-Cell Engaging Bispecific Antibodies by Region (2023-2028)
2.5 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Region
2.5.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Region (2017-2022)
2.5.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Manufacturers
3.1.1 Global Top T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturers by Sales (2017-2022)
3.1.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of T-Cell & NK-Cell Engaging Bispecific Antibodies in 2021
3.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Manufacturers
3.2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Manufacturers (2017-2022)
3.2.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue in 2021
3.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type
4.1.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Historical Sales by Type (2017-2022)
4.1.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Sales by Type (2023-2028)
4.1.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Type (2017-2028)
4.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Type
4.2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Historical Revenue by Type (2017-2022)
4.2.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Revenue by Type (2023-2028)
4.2.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Type (2017-2028)
4.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Price by Type
4.3.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Price by Type (2017-2022)
4.3.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application
5.1.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Historical Sales by Application (2017-2022)
5.1.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Sales by Application (2023-2028)
5.1.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Application (2017-2028)
5.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Application
5.2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Historical Revenue by Application (2017-2022)
5.2.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Revenue by Application (2023-2028)
5.2.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Application (2017-2028)
5.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Price by Application
5.3.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Price by Application (2017-2022)
5.3.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Price Forecast by Application (2023-2028)
6 North America
6.1 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type
6.1.1 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type (2017-2028)
6.1.2 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Type (2017-2028)
6.2 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application
6.2.1 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application (2017-2028)
6.2.2 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Application (2017-2028)
6.3 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country
6.3.1 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2017-2028)
6.3.2 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type
7.1.1 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type (2017-2028)
7.1.2 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Type (2017-2028)
7.2 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application
7.2.1 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application (2017-2028)
7.2.2 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Application (2017-2028)
7.3 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country
7.3.1 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2017-2028)
7.3.2 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type
8.1.1 Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type (2017-2028)
8.1.2 Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Type (2017-2028)
8.2 Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application
8.2.1 Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application (2017-2028)
8.2.2 Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Application (2017-2028)
8.3 Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Region
8.3.1 Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region (2017-2028)
8.3.2 Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type
9.1.1 Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type (2017-2028)
9.1.2 Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Type (2017-2028)
9.2 Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application
9.2.1 Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application (2017-2028)
9.2.2 Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Application (2017-2028)
9.3 Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country
9.3.1 Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2017-2028)
9.3.2 Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type
10.1.1 Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type (2017-2028)
10.1.2 Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Type (2017-2028)
10.2 Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application
10.2.1 Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application (2017-2028)
10.2.2 Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Application (2017-2028)
10.3 Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country
10.3.1 Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2017-2028)
10.3.2 Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 AbbVie
11.1.1 AbbVie Corporation Information
11.1.2 AbbVie Overview
11.1.3 AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 AbbVie Recent Developments
11.2 Astellas Pharma
11.2.1 Astellas Pharma Corporation Information
11.2.2 Astellas Pharma Overview
11.2.3 Astellas Pharma T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Astellas Pharma T-Cell & NK-Cell Engaging Bispecific Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Astellas Pharma Recent Developments
11.3 GEMoaB Monoclonals
11.3.1 GEMoaB Monoclonals Corporation Information
11.3.2 GEMoaB Monoclonals Overview
11.3.3 GEMoaB Monoclonals T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 GEMoaB Monoclonals T-Cell & NK-Cell Engaging Bispecific Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 GEMoaB Monoclonals Recent Developments
11.4 Immunocore
11.4.1 Immunocore Corporation Information
11.4.2 Immunocore Overview
11.4.3 Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Immunocore Recent Developments
11.5 Molecular Partners
11.5.1 Molecular Partners Corporation Information
11.5.2 Molecular Partners Overview
11.5.3 Molecular Partners T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Molecular Partners T-Cell & NK-Cell Engaging Bispecific Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Molecular Partners Recent Developments
11.6 Roche
11.6.1 Roche Corporation Information
11.6.2 Roche Overview
11.6.3 Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Roche Recent Developments
11.7 AstraZeneca
11.7.1 AstraZeneca Corporation Information
11.7.2 AstraZeneca Overview
11.7.3 AstraZeneca T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 AstraZeneca T-Cell & NK-Cell Engaging Bispecific Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 AstraZeneca Recent Developments
11.8 Merck & Co.
11.8.1 Merck & Co. Corporation Information
11.8.2 Merck & Co. Overview
11.8.3 Merck & Co. T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Merck & Co. T-Cell & NK-Cell Engaging Bispecific Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Merck & Co. Recent Developments
11.9 Pfizer
11.9.1 Pfizer Corporation Information
11.9.2 Pfizer Overview
11.9.3 Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Pfizer Recent Developments
11.10 Eli Lilly
11.10.1 Eli Lilly Corporation Information
11.10.2 Eli Lilly Overview
11.10.3 Eli Lilly T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Eli Lilly T-Cell & NK-Cell Engaging Bispecific Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Eli Lilly Recent Developments
11.11 IGM Biosciences
11.11.1 IGM Biosciences Corporation Information
11.11.2 IGM Biosciences Overview
11.11.3 IGM Biosciences T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 IGM Biosciences T-Cell & NK-Cell Engaging Bispecific Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 IGM Biosciences Recent Developments
11.12 Novartis
11.12.1 Novartis Corporation Information
11.12.2 Novartis Overview
11.12.3 Novartis T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Novartis T-Cell & NK-Cell Engaging Bispecific Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Novartis Recent Developments
11.13 BenHealth Biopharmaceuticals
11.13.1 BenHealth Biopharmaceuticals Corporation Information
11.13.2 BenHealth Biopharmaceuticals Overview
11.13.3 BenHealth Biopharmaceuticals T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 BenHealth Biopharmaceuticals T-Cell & NK-Cell Engaging Bispecific Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 BenHealth Biopharmaceuticals Recent Developments
11.14 CytomX Therapeutics
11.14.1 CytomX Therapeutics Corporation Information
11.14.2 CytomX Therapeutics Overview
11.14.3 CytomX Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 CytomX Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 CytomX Therapeutics Recent Developments
11.15 Janssen
11.15.1 Janssen Corporation Information
11.15.2 Janssen Overview
11.15.3 Janssen T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Janssen T-Cell & NK-Cell Engaging Bispecific Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Janssen Recent Developments
11.16 Lava Therapeutics
11.16.1 Lava Therapeutics Corporation Information
11.16.2 Lava Therapeutics Overview
11.16.3 Lava Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Lava Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Lava Therapeutics Recent Developments
11.17 MacroGenics
11.17.1 MacroGenics Corporation Information
11.17.2 MacroGenics Overview
11.17.3 MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 MacroGenics Recent Developments
11.18 Maverick Therapeutics
11.18.1 Maverick Therapeutics Corporation Information
11.18.2 Maverick Therapeutics Overview
11.18.3 Maverick Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 Maverick Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Maverick Therapeutics Recent Developments
11.19 VBL Therapeutics
11.19.1 VBL Therapeutics Corporation Information
11.19.2 VBL Therapeutics Overview
11.19.3 VBL Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 VBL Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 VBL Therapeutics Recent Developments
11.20 Amgen
11.20.1 Amgen Corporation Information
11.20.2 Amgen Overview
11.20.3 Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.20.4 Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 Amgen Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Chain Analysis
12.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Production Mode & Process
12.4 T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Marketing
12.4.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Channels
12.4.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Distributors
12.5 T-Cell & NK-Cell Engaging Bispecific Antibodies Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Trends
13.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Drivers
13.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Challenges
13.4 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Restraints
14 Key Findings in The Global T-Cell & NK-Cell Engaging Bispecific Antibodies Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer